Barlow Carrolee has filed 16 insider transactions across 1 company since February 2023.
Most recent transaction: a disposition of 4475 shares of SUPERNUS PHARMACEUTICALS, INC. ($SUPN) on February 24, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 24, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | D | Restricted Stock Unit | 4475 | $0.00 | 0.0000 | 56,552,741 | 100.00% | 0.01% |
| Feb. 24, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Common Stock | 4475 | $0.00 | 27,045.0000 | 56,552,741 | 19.83% | 0.01% |
| Feb. 18, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Director Stock Option (Right to Buy) | 4977 | $0.00 | 4,977.0000 | 56,552,741 | 9999.99% | 0.01% |
| Feb. 18, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Restricted Stock Unit | 2989 | $0.00 | 2,989.0000 | 56,552,741 | 9999.99% | 0.01% |
| Feb. 22, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Common Stock | 5369 | $0.00 | 22,570.0000 | 55,958,537 | 31.21% | 0.01% |
| Feb. 22, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | D | Restricted Stock Units | 5369 | $0.00 | 0.0000 | 55,958,537 | 100.00% | 0.01% |
| Feb. 19, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Director Stock Option (Right to Buy) | 7296 | $0.00 | 7,296.0000 | 55,958,537 | 9999.99% | 0.01% |
| Feb. 19, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Restricted Stock Unit | 4475 | $0.00 | 4,475.0000 | 55,958,537 | 9999.99% | 0.01% |
| Feb. 23, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Common Stock | 3886 | $0.00 | 17,201.0000 | 55,506,828 | 29.19% | 0.01% |
| Feb. 23, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | D | Restricted Stock Units | 3886 | $0.00 | 0.0000 | 55,506,828 | 100.00% | 0.01% |
| Feb. 22, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Director Stock Option (Right to Buy) | 8252 | $0.00 | 8,252.0000 | 55,506,828 | 9999.99% | 0.01% |
| Feb. 22, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Restricted Stock Units | 5369 | $0.00 | 5,369.0000 | 55,506,828 | 9999.99% | 0.01% |
| Feb. 23, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Restricted Stock Units | 3886 | $0.00 | 3,886.0000 | 61,679,800 | 9999.99% | 0.01% |
| Feb. 23, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Director Stock Option (Right to Buy) | 6293 | $0.00 | 6,293.0000 | 61,679,800 | 9999.99% | 0.01% |
| Feb. 22, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | D | Restricted Stock Units | 3882 | $0.00 | 0.0000 | 61,679,800 | 100.00% | 0.01% |
| Feb. 22, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Barlow Carrolee | Director | A | Common Stock | 3882 | $0.00 | 13,315.0000 | 61,679,800 | 41.15% | 0.01% |